The management of hypertension in ischaemic heart disease

Current Opinion in Cardiology

Volumn 21, Issue 4, 2006, Pages 273-278

  Hawkins, Nathaniel M ^a   Dunn, Francis G ^a  

^a STOBHILL HOSPITAL   (United Kingdom)

Author keywords

Antihypertensive agents; Coronary artery disease; Hypertension; Statins

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; METOPROLOL; NIFEDIPINE; PERINDOPRIL; SIMVASTATIN; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EXERCISE; HEART MUSCLE OXYGEN CONSUMPTION; HEART REHABILITATION; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MYOPATHY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SHOCK; SMOKING CESSATION; TREATMENT FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 33748188871     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000231395.79609.6d     Document Type: Review

References (42)

1. Boersma E, Keil U, De Bacquer D, et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003; 21:1831-1840.
2. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
3. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-Inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25:1454-1470.
4. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
5. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45:813-827. Comprehensive review highlighting the importance of blood pressure reduction and statin therapy.
6. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033. Meta-analysis suggesting that the renoprotective effects of ACE inhibitors probably result from blood pressure lowering.
7. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
8. Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358:2130-2131.
9. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38:E28-E32.
10. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
11. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction: may they rest in PEACE? N Engl J Med 2004; 351:2115-2117.
12. Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease [letter]. N Engl J Med 2005; 352:937-939. Correspondence offering reasons for the absence of benefit observed in the PEACE trial.
13. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). www.acc.org/clinical/guidelines/stable/stable.pdf (accessed 1 December 2005).
14. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
15. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684-1689.
16. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553. Exceptionally important meta-analysis indicating that β-blockers reduce risk of stroke less than other antihypertensive drugs. β-Blockers may therefore no longer be appropriate first-choice drugs in primary hypertension.
17. Abrams J. Clinical practice: chronic stable angina. N Engl J Med 2005; 352:2524-2533.
18. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281:1927-1936.
19. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. Huge hypertension trial in which the amlodipine-perindopril strategy reduced cardiovascular mortality and major cardiovascular events compared with the atenolol-bendroflumethiazide regimen.
20. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730-1737.
21. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622-1632. Results of COMMIT indicate that β-blocker therapy after myocardial infarction is best commenced once a patient's haemodynamic condition has stabilized. The very large number of participants provided sufficient statistical power to examine many subgroups of interest.
22. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849-857.
23. Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23:641-648. The calcium channel blocker nifedipine (GITS) reduced cardiovascular events in the prespecified subgroup with stable angina and hypertension.
24. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217-2225.
25. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
26. Sever PS, Poulter NR, Dahlof B, et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96:39F-44F.
27. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
28. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435. Intensive lipid lowering with atorvastatin 80 mg significantly reduced major cardiovascular events. A nonsignificant increase in noncardiovascular death tempered results.
29. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease: is it time to shift our goals? N Engl J Med 2005; 352:1483-1484.
30. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445. Concerns regarding the safety of high-dose atorvastatin were lessened. Noncardiovascular death was similar in the two groups.
31. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278. Largest meta-analysis of statin trials to date. The magnitude of cardiovascular benefit relates to absolute reductions in LDL-c, irrespective of the baseline lipid profile.
32. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
33. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
34. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. Heart 2005; 91(Suppl 5):v1-v52. Consensus opinion of British Societies regarding management of cardiovascular risk. Low targets for blood pressure and cholesterol are recommended.
35. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
36. Pardell H, Rodicio JL. High blood pressure, smoking and cardiovascular risk. J Hypertens 2005; 23:219-221. Excellent concise overview of the effects of smoking and importance of cessation in patients with hypertension.
37. Thompson PD. Exercise prescription and proscription for patients with coronary artery disease. Circulation 2005; 112:2354-2363.
38. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116:682-692.
39. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004; 109:1371-1378.
40. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005; 111:2906-2912. Meta-analysis of trials comparing percutaneous intervention with medical therapy. The results offer little support for the invasive approach adopted by many cardiologists.
41. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113:203-212. This study highlights the poor adherence among patients to core evidence-based therapies.
42. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180-189. Despite guidelines, this large international registry demonstrates that major cardiovascular risk factors remain largely undertreated.